DiaSorin

Update in progress

DIA.MI (Milan)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostic and molecular diagnostic tests worldwide. It offers immunodiagnostic assays for infectious diseases, endocrinology, GI infections, autoimmunity, hypertension, sepsis, bone metabolism, and oncology under the LIAISON XL/XS platforms. It also markets Simplexa CMV direct kit (saliva/urine), LIAISON PLEX Respiratory Flex and Yeast Blood Culture Assays, and the xMAP technology platform. Founded in 1968, based in Saluggia, Italy.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.43; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive